Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03526666 · ClinicalTrials.gov registry record

Ascorbic Acid Levels in MDS, AML, and CMML Patients

A clinical trial of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Van Andel Research Institute.

Completed
Registry status
50
Enrollment target
2
Study locations

NCT03526666: Completed study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Van Andel Research Institute.

NCT03526666 is a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that has completed, run by Van Andel Research Institute. The registered enrollment target is 50 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03526666, a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Van Andel Research Institute.

COMPLETED
Registry status
50 participants
Enrollment target
2
Study locations

Study Summary

This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.

Primary Outcome

The level of ascorbic acid

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia AML MDS CMML

Interventions

  • OTHER Peripheral blood collection

Study Locations (2)

Michigan

  • Cancer and Hematology Centers of Western Michigan - Grand Rapids
  • Metro Health - University of Michigan Health - Wyoming

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2017-11-01
Est. Completion 2018-10-31
Van Andel Research Institute

3 total trials

What the finished NCT03526666 record still lists

NCT03526666 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (57% lower).

The record links to 6 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Peripheral blood collection is the first listed.

NCT03526666 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT03526666 about?

NCT03526666 is a clinical study titled "Ascorbic Acid Levels in MDS, AML, and CMML Patients". This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.

What is the current status of trial NCT03526666?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2017-11-01. Estimated completion is 2018-10-31.

What conditions does trial NCT03526666 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS.

What interventions are being tested in trial NCT03526666?

The interventions under investigation include: Peripheral blood collection (OTHER).

Who is sponsoring clinical trial NCT03526666?

This trial is sponsored by Van Andel Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03526666 being conducted?

This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03526666's enrollment target sits among peer trials

50 143rd of 306 higher than 154 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03526666, the US trial registry maintained by the National Library of Medicine. NCT03526666 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.